Skip to main content
Bio-Thera Solutions, Ltd. logo

Bio-Thera Solutions, Ltd. — Investor Relations & Filings

Ticker · 688177 ISIN · CNE100003R98 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 691 across all filing types
Latest filing 2022-08-23 Interim / Quarterly Rep…
Country CN China
Listing Shanghai Stock Exchange 688177

About Bio-Thera Solutions, Ltd.

https://www.bio-thera.com/

Bio-Thera Solutions, Ltd. is a biopharmaceutical company dedicated to the research and development of innovative therapeutics and high-quality biosimilars. The company focuses on addressing serious medical conditions across oncology, autoimmune, and cardiovascular therapeutic areas. Its portfolio includes several approved biosimilars, such as QLETLI (adalimumab), POBEVCY (bevacizumab), and TOFIDENCE (tocilizumab), alongside a robust pipeline of novel drug candidates, including antibody-drug conjugates (ADCs) and monoclonal antibodies. Bio-Thera utilizes advanced technology platforms to streamline the drug discovery and development process, aiming to expand global access to essential biologic medicines. The organization maintains a commitment to rigorous clinical standards and international regulatory compliance to deliver effective treatment options for patients worldwide.

Recent filings

Filing Released Lang Actions
百奥泰2022年半年度报告摘要
Interim / Quarterly Report Classification · 95% confidence The document is titled as a '2022 半年度报告摘要' which translates to '2022 Half-Year Report Summary'. It contains detailed financial data such as total assets, net profit, revenue, and shareholder information for the half-year period. The document explicitly states it is a half-year report summary and references the full half-year report for comprehensive details. The length is under 5,000 characters but contains substantive financial data and analysis, not just an announcement or a link to a report. Therefore, it qualifies as an Interim / Quarterly Report (IR).
2022-08-23 Chinese
百奥泰生物制药股份有限公司内幕信息知情人登记管理制度
Governance Information Classification · 95% confidence The document is a detailed internal management system for insider information registration and confidentiality at 百奥泰生物制药股份有限公司. It outlines rules, responsibilities, and procedures related to insider information management, confidentiality, and compliance with relevant Chinese securities laws and stock exchange regulations. There is no financial data, earnings information, or report publication. It is not an announcement or a transcript but a governance-related document detailing internal rules and compliance practices. Therefore, it fits best under Governance Information (CGR). The document length and content confirm it is a substantive governance policy document, not a brief announcement or regulatory filing.
2022-08-23 Chinese
中国国际金融股份有限公司关于百奥泰生物制药股份有限公司使用部分闲置募集资金暂时补充流动资金的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed verification opinion from a sponsoring institution (China International Capital Corporation Limited) regarding the use of temporarily idle raised funds by Bai'ao Tai Biopharmaceutical Co., Ltd. It references regulatory rules related to the management and use of raised funds, details the approval process by the board and supervisory committee, and confirms compliance with relevant regulations. The document is not a full annual or interim financial report, nor is it an earnings release or a call transcript. It is not a proxy statement or voting result announcement. It is a formal verification or audit-type opinion related to the use of funds raised in an IPO and their temporary allocation to working capital. This fits the definition of an Audit Report / Information (AR) as it involves audit verification and compliance opinions on the use of funds, but is not a full annual report or financial statement. The document length (5973 characters) and content support this classification rather than a simple announcement or regulatory filing. Therefore, the best classification is AR with high confidence.
2022-08-23 Chinese
百奥泰 关于公司及相关人员收到中国证券监督管理委员会广东监管局警示函的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from 百奥泰生物制药股份有限公司 regarding receipt of a warning letter from the China Securities Regulatory Commission Guangdong Bureau. It details regulatory findings about financial accounting inaccuracies, insider information management issues, and fundraising management problems. The document does not contain financial statements or detailed financial data but rather describes regulatory actions and company responses. It is a regulatory announcement about legal and compliance matters, not a financial report or earnings release. Therefore, it fits best under Regulatory Filings (RNS). The document length is short (2229 characters), and it is not a report publication announcement or certification letter, but a regulatory compliance announcement.
2022-08-19 Chinese
百奥泰关于收到增值税留抵退税的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (489 characters) regarding the receipt of a VAT refund by the company 百奥泰生物制药股份有限公司. It includes a statement about the impact on cash flow and accounting treatment but does not contain detailed financial statements or comprehensive financial data. It is an update on a specific financial event (tax refund) rather than a full financial report or earnings release. The document is an official announcement to inform investors about a financial event affecting the company. Given its brevity and nature, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2022-08-08 Chinese
百奥泰关于获得政府补助的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (470 characters) about the company receiving government subsidies, including the amount and accounting treatment. It explicitly states that the subsidies are unaudited and that the final impact will be confirmed by the annual audit. There is no detailed financial data or comprehensive report content. The document serves as a regulatory announcement informing investors about the subsidy receipt and related risks. It does not qualify as an Annual Report, Interim Report, or Audit Report. It is not a report publication announcement since it contains substantive information rather than just a notice of report availability. Therefore, the best fitting category is Regulatory Filings (RNS), which covers miscellaneous regulatory announcements that do not fit other categories.
2022-08-05 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.